These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 32739228)

  • 1. Concordance of confirmatory prostate biopsy in active surveillance with national guidelines: An analysis from the multi-institutional PURC cohort.
    Talwar R; Friel B; Mittal S; Xia L; Fonshell C; Danella J; Jacobs B; Lanchoney T; Raman J; Tomaszewski J; Trabulsi E; Reese A; Singer EA; Ginzburg S; Smaldone M; Uzzo R; Mucksavage P; Guzzo TJ; Lee DJ
    Urol Oncol; 2020 Nov; 38(11):846.e17-846.e22. PubMed ID: 32739228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.
    Botejue M; Abbott D; Danella J; Fonshell C; Ginzburg S; Guzzo TJ; Lanchoney T; Marlowe B; Raman JD; Smaldone M; Tomaszewski JJ; Trabulsi EJ; Uzzo RG; Reese AC
    J Urol; 2019 May; 201(5):929-936. PubMed ID: 30720692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.
    Luckenbaugh AN; Auffenberg GB; Hawken SR; Dhir A; Linsell S; Kaul S; Miller DC;
    J Urol; 2017 Mar; 197(3 Pt 1):621-626. PubMed ID: 27663459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transperineal Template Guided Prostate Biopsy Selects Candidates for Active Surveillance--How Many Cores are Enough?
    Pham KN; Porter CR; Odem-Davis K; Wolff EM; Jeldres C; Wei JT; Morgan TM
    J Urol; 2015 Sep; 194(3):674-9. PubMed ID: 25963186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
    Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
    J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.
    Schoots IG; Nieboer D; Giganti F; Moore CM; Bangma CH; Roobol MJ
    BJU Int; 2018 Dec; 122(6):946-958. PubMed ID: 29679430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?
    Pepe P; Garufi A; Priolo G; Pennisi M
    World J Urol; 2016 Sep; 34(9):1249-53. PubMed ID: 26699628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
    Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
    J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer.
    Wong LM; Ferrara S; Alibhai SM; Evans A; Van der Kwast T; Trottier G; Timilshina N; Toi A; Kulkarni G; Hamilton R; Zlotta A; Fleshner N; Finelli A
    Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):69-74. PubMed ID: 25487136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
    Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
    Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of perineural invasion and race in men considering active surveillance.
    Cohn JA; Dangle PP; Wang CE; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    BJU Int; 2014 Jul; 114(1):75-80. PubMed ID: 24106869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
    Kaye DR; Qi J; Morgan TM; Linsell S; Ginsburg KB; Lane BR; Montie JE; Cher ML; Miller DC;
    BJU Int; 2019 May; 123(5):846-853. PubMed ID: 30248225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?
    Satasivam P; Poon BY; Ehdaie B; Vickers AJ; Eastham JA
    J Urol; 2016 Jan; 195(1):74-9. PubMed ID: 26192258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance.
    Dai C; Ganesan V; Nyame YA; Almassi N; Greene DJ; Hettel D; Magi-Galluzzi C; Gong M; Jones JS; Stephenson AJ; Berglund RK; Klein EA
    Urology; 2019 Aug; 130():106-112. PubMed ID: 31071349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
    Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.
    Bloom JB; Hale GR; Gold SA; Rayn KN; Smith C; Mehralivand S; Czarniecki M; Valera V; Wood BJ; Merino MJ; Choyke PL; Parnes HL; Turkbey B; Pinto PA
    J Urol; 2019 Jan; 201(1):84-90. PubMed ID: 30577395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.